1. Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration- resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint 
Ethan M. Basch, Mark Scholz, Johann S. de Bono, Nicholas Vogelzang, Paul de Souza, Gavin Marx, Ulka Vaishampayan, Saby George, James K. Schwarz, Emmanuel S. Antonarakis, Joseph M. O'Sullivan, Arash Rezazadeh Kalebasty, Kim N. Chi, Robert Dreicer, Thomas E. Hutson, Amylou C. Dueck, Antonia V. Bennett, Erica Dayan, Milan Mangeshkar, Jaymes Holland, Aaron L. Weitzman, Howard I. Scher 
European Urology 
DOI: /j.eururo
Copyright © 2018 The Authors Terms and Conditions

2. Fig. 1
CONSORT diagram. Patient disposition shown at the time of study closure. Two patients did not receive study treatment because of eligibility violations that were discovered after randomization but before initiation of study treatment. ITT=intent to treat.
European Urology DOI: ( /j.eururo )
Copyright © 2018 The Authors Terms and Conditions